PF-07225570 / Pfizer - LARVOL DELTA

PF-07225570 Alone or in Combination With an Anti-PD-1 Antibody in Recurrent Non-muscle Invasive Bladder Cancer (NMIBC) (clinicaltrials.gov) - P1 | N=0 | Withdrawn | Sponsor: Pfizer | Trial completion date: Apr 2028 ➔ Sep 2022 | Trial primary completion date: Mar 2027 ➔ Sep 2022

Combination therapy • Trial completion date • Trial primary completion date • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • Urothelial Cancer

PF-07225570 Alone or in Combination With an Anti-PD-1 Antibody in Recurrent Non-muscle Invasive Bladder Cancer (NMIBC) (clinicaltrials.gov) - P1 | N=0 | Withdrawn | Sponsor: Pfizer | N=130 ➔ 0 | Recruiting ➔ Withdrawn

Combination therapy • Enrollment change • Trial withdrawal • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • Urothelial Cancer

PF-07225570 Alone or in Combination With an Anti-PD-1 Antibody in Recurrent Non-muscle Invasive Bladder Cancer (NMIBC) (clinicaltrials.gov) - P1 | N=130 | Recruiting | Sponsor: Pfizer | Trial completion date: May 2027 ➔ Apr 2028 | Trial primary completion date: Apr 2026 ➔ Mar 2027

Combination therapy • Trial completion date • Trial primary completion date • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • Urothelial Cancer

PF-07225570 Alone or in Combination With an Anti-PD-1 Antibody in Recurrent Non-muscle Invasive Bladder Cancer (NMIBC) (clinicaltrials.gov) - P1 | N=130 | Recruiting | Sponsor: Pfizer | Not yet recruiting ➔ Recruiting

Combination therapy • Enrollment open • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • Urothelial Cancer